【摘要】 目的了解复方维生素B12和重组人表皮生长因子治疗鼻咽癌放疗引起的口腔黏膜炎的疗效和效价比。方法将80例因鼻咽癌需行放疗的患者随机分为治疗组Ⅰ和治疗组Ⅱ各40例,两组均给予医用直线加速器或60Co照射,剂量均为每次2Gy,每周5次,共放疗6周。患者均在放疗开始后第2周出现口腔黏膜炎。于放疗2周后开始口腔喷雾给药,治疗组Ⅰ给予复方维生素B12,每次2mL,tid;治疗组Ⅱ给予重组人表皮生长因子,每次1mL,每天2或3次。连续用药至放疗结束。记录两组的不良反应、治疗费用和疗效。结果治疗组Ⅰ口腔黏膜炎治疗有效率为87.5%,治疗组Ⅱ有效率为92.5%,两组有效率差异无显著性(P>0.05),但治疗组Ⅰ效价比高于治疗组Ⅱ。结论从药物经济学角度看,治疗鼻咽癌放疗引起的口腔黏膜炎时选用复方维生素B12效价比相对较高。更多还原

【Abstract】 Objective To study the therapeutic effectiveness and effect-cost ratio of compound Vitamin B₁2 and recombinant human epidermal growth factor（rhEGF） in the treatment of oral mucositis caused by radiotherapy in patients with nasopharyngeal carcinoma（NPC）. Methods 80 cases of NPC scheduled for radiotherapy were randomly divided into 2 equal groups, group Ⅰand group Ⅱ .Patients of both groups were submitted to linear acceleration or ⁶0Co radiotherapy. The dose of the radiotherapy was 2 Gy per time, 5 times a week. The course of treatment lasted 6 weeks. Oral mucositis began to appear in patients in the 2 ⁿd week of radiotherapy. Beginning from this week, patients of group Ⅰand group Ⅱ were given each 2 mL of compound vitamin B₁2 ,t.i.d. and 1 mL of rhEGF b.i.d. or t.i.d., respectively, administered by oral spraying. This treatment persisted until the termination of radiotherapy. Adverse reactions ,costs and therapeutic effects of the 2 drugs were registered for analysis.. Results The effective rates of compound vitamin B₁2 and rhEGF in the treatment of oral mucositis in patients of groupⅠand groupⅡwere 87.5% and 92.5% ,respectively, the difference being insignificant （P>0.05）. However, the cost of compound vitamin B₁2 （296.00 yuan） was significantly lower than that of rhECF （583.00 yuan）. Conclusion From the viewpoint of pharmacoeconomics ,it seems preferable to use compound vitamin B₁2 with a higher effect/cost ratio in the treatment of oral mucositis caused by radiotherapy in patients with NPC.更多还原